Gene Signal promise for topical AMD antisense treatment
This article was originally published in Scrip
Gene Signal's topical anti-angiogenic eye therapy aganirsen could be effective in preventing vascularisation at the back of the eye, new data suggest, potentially opening up a new way of treating diseases such as wet AMD and ischaemic retinopathy.
You may also be interested in...
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.